title: New drugs 2011 part 2.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D003281:Contraceptives, Postcoital / Q000009:adverse effects / Q000627:therapeutic use; D000069604:Dabigatran; D004358:Drug Therapy / Q000451:nursing*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009649:Norpregnadienes / Q000009:adverse effects / Q000627:therapeutic use; D004364:Pharmaceutical Preparations; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D003281:Contraceptives, Postcoital; D005343:Fibrinolytic Agents; D007166:Immunosuppressive Agents; D009649:Norpregnadienes; D004364:Pharmaceutical Preparations; D011409:Propylene Glycols; D011725:Pyridines; D000068876:Fingolimod Hydrochloride; D000069604:Dabigatran; D013110:Sphingosine; C555622:ulipristal acetate